Device Hernia Repair

Transorb

Payments companies reported to CMS as associated with Transorb. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$116Kassociated payments (2023-2025)

697clinicians with associated payments

1company reporting

By year

2024 $904

2025 $115K

Payments reported as associated with Transorb, per program year, as reported to CMS.

Who makes it

Medtronic, INC. $116K associated with Transorb (2023-2025)

Specialties most often involved

Surgery $98K

Physician Assistant $3,103

Surgical Critical Care $1,200

Surgical $1,061

Trauma Surgery $1,045

Family $847

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Transorb

These are the largest totals companies reported as associated with Transorb. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Steven Hopson	Newport News, VA	Surgery	$17,727.80
Vedra Augenstein	Charlotte, NC	Surgery	$15,012.78
Namir Katkhouda	Los Angeles, CA	Surgery	$8,665.83
Charlotte Horne	Rochester, MN	Surgery	$6,535.30
Jin Yoo	Durham, NC	Surgery	$4,728.47
Lucian Panait	Chaska, MN	Surgery	$4,312.91
Anthony Zappia	Carmel, IN	Surgery	$766.33
Erica Sudyk	Durham, NC	Physician Assistant	$685.38
Daniel Marcus	Marina Del Rey, CA		$605.77
Kevin Lynch	Slidell, LA	Surgery	$525.57

Prescribed Transorb?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.